- Allogene Therapeutics Announces Q2 Investor Conference Participation
- Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
- Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
- Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
- Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
- Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia
- Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
- Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
- Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
- Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference
More ▼
Key statistics
As of last trade, Allogene Therapeutics Inc (ALLO:NSQ) traded at 3.51, 57.40% above the 52 week low of 2.23 set on Dec 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.45 |
---|---|
High | 3.52 |
Low | 3.40 |
Bid | 3.50 |
Offer | 3.51 |
Previous close | 3.46 |
Average volume | 1.84m |
---|---|
Shares outstanding | 169.09m |
Free float | 112.43m |
P/E (TTM) | -- |
Market cap | 585.06m USD |
EPS (TTM) | -2.09 USD |
Data delayed at least 15 minutes, as of Apr 19 2024 14:41 BST.
More ▼